Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors.

Eur J Pharm Biopharm

Technische Universität Braunschweig, Institut für Medizinische und Pharmazeutische Chemie, Beethovenstraβe 55, 38106 Braunschweig, Germany; Technische Universität Braunschweig, Center of Pharmaceutical Engineering (PVZ), Franz-Liszt-Straβe 35A, D-38106 Braunschweig, Germany. Electronic address:

Published: May 2018

Rearrangements of anaplastic lymphoma kinase (ALK) are associated with several cancer diseases. Due to resistance development against existing ALK-inhibitors, new, structurally unrelated inhibitors are required. By a scaffold hopping strategy, 6,8-disubstituted purines were designed as analogues of similar ALK-inhibiting thieno[3,2-d]pyrimidines. While the new title compounds indeed inhibited ALK and several ALK mutants in submicromolar concentrations, they retained poor water solubility.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2017.03.011DOI Listing

Publication Analysis

Top Keywords

scaffold hopping
8
68-disubstituted purines
8
anaplastic lymphoma
8
lymphoma kinase
8
hopping identifies
4
identifies 68-disubstituted
4
purines novel
4
novel anaplastic
4
kinase inhibitors
4
inhibitors rearrangements
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!